BPH Treatment Landscape Update Q1 2026: New FDA Approvals, Category I Transitions, and Label Expansions
- Catherine Song, PhD.
- Jan 27
- 3 min read
Updated: Mar 6
At a Glance
Two new prostatic urethral stents approved by FDA (December 2025)
Three major therapies transition to Category I CPT codes (Since January 2025)
Rezūm expands indication to prostates up to 150cc
Pipeline of three additional devices
As we enter 2026, the treatment landscape is shifting rapidly. With three major therapies transitioning to Category I status this month and two new FDA approvals just weeks ago, the "MIST toolkit" (Minimally Invasive Surgical Therapies) has never been more robust. We've compiled the essential regulatory, reimbursement, and clinical updates to help you navigate these changes in your practice.
New Entrants: FDA Approvals (December 2025)
The FDA closed out 2025 by approving two new prostatic urethral stent systems, signaling a high priority for minimally invasive, "non-thermal" solutions.
ProVee System (ProVerum)
FDA Approval: December 9, 2025
Supported by the ProVIDE trial, showing 125% greater IPSS improvement vs. sham at 3 months with no sustained sexual dysfunction.
Zenflow Spring Implant (Zenflow)
FDA Approval: December 11, 2025
Based on the BREEZE study showing a 37% IPSS improvement vs. sham with no device-related serious adverse events.
Major Reimbursement Milestones (Effective January 1, 2026)
CMS has officially recognized the clinical maturity of three key therapies by transitioning them to Category I CPT codes, significantly reducing the "prior auth" burden.
What is Category I Status?
Category I CPT codes represent established procedures with proven clinical evidence. The transition from Category III (temporary/investigational) to Category I means:
Easier insurance coverage - Most payers automatically recognize these codes
Reduced prior authorization - Less administrative burden for practices
Clinical validation - Recognition of sufficient safety and efficacy data
Improved reimbursement predictability - More standardized payment rates
The Three Transitions
Aquablation (Procept BioRobotics): Now uses code 52597.
Optilume BPH (Urotronic/Laborie): Transitions from Cat III to Code 52443.
iTind (Olympus): Now fully established in Category I (Codes 53865 for insertion; 53866 for removal) since Jan 1, 2025.
Label Expansions: Rezūm Up to 150cc
In a significant competitive shift, Rezūm (Boston Scientific) received expanded clearance for prostates up to 150cc (previously 30-80cc).
The Data
Supported by a meta-analysis of 471 patients with large glands (≥80cc), showing low surgical retreatment rate: 1.2% at median follow-up of 6 months
The Impact
This positions Rezūm as a viable office-based alternative for patients who previously would have required HoLEP (Holmium Laser Enucleation) or simple prostatectomy.
Pipeline Watch: What's Next for 2026
Butterfly Device: Pivotal trial completed (Jan. 2026). This prostatic retraction device is awaiting an FDA PMA decision.
Rivermark FloStent: The RAPID III trial is currently enrolling. This "zero-capital" procedure is designed to be used with any standard flexible cystoscope.
Prodeon Urocross Expander: Enrollment for the EXPANDER-2 study is complete. This 6-month temporary nitinol implant offers a "remodeling" approach without permanent hardware.
The Bottom Line
New devices (ProVee, Zenflow) expand the treatment options
Improved coverage (Category I transitions) reduces insurance barriers
Expanded indications (Rezūm to 150cc) bring office-based care to larger prostates
Growing pipeline (Butterfly, FloStent, Urocross) continues innovation
The challenge: Navigating this complexity requires systematic patient selection and outcome tracking.
The opportunity: Personalized BPH care matching individual anatomy, preferences, and priorities.
proudP is an at-home urine flow test app that uses acoustic AI to measure urine flow with your smartphone.
Try out proudP
Take the full IPSS questionnaire—the same test doctors use.
Test your urine flow strength at home.
FAQ
Which BPH treatments are minimally invasive?
Minimally invasive options include UroLift, Rezum, and iTind. These can be performed in an office or ambulatory surgery center, often without general anesthesia, and usually have shorter recovery times than surgery.
What is the difference between office procedures and ASC procedures?
Office procedures are done during a regular doctor’s visit with minimal equipment, while ASC (Ambulatory Surgery Center) procedures are performed in specialized outpatient centers with more advanced tools. Both let you go home the same day.
Is Aquablation covered by insurance?
Aquablation currently has limited insurance coverage in the U.S., as it is billed under a Category III T-Code. Check with your provider for details on your plan.
What is iTind and how does it work?
iTind is a temporary stent placed in the prostate for about 7 days. It reshapes the prostate tissue to relieve symptoms without permanent implants or major surgery. It became eligible for Medicare coverage in 2025.
Which BPH procedure offers the fastest recovery?
Recovery time varies, but office-based procedures like UroLift and Rezum generally have faster recovery than surgeries like TURP or HoLEP.
Can I monitor my urinary health at home after BPH treatment?
Yes. Apps like proudP allow you to measure your urinary flow at home, similar to a clinic’s uroflowmetry test, so you can track your recovery and treatment effectiveness over time.
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Treatment decisions should be made in consultation with qualified healthcare providers based on individual patient circumstances
